The Society aims to plan collaborative projects requiring larger numbers than possible at one centre. Individuals may also seek to involve other
News & Social Feeds
News and Information from the British Heart Valve Society.
Annual Meeting 2018
Information and presentation from the BHVS Annual Meeting held in September 2018.
11 hours ago
Full house for #HeadStart2018! Amazing lineup of speakers to tell our first year #cardiology registrars what they wished they new when they first started out #cardioed https://t.co/fcMze8sKiX
Full house for #HeadStart2018! Amazing lineup of speakers to tell our first year #cardiology registrars what they wished they new when they first started out #cardioed https://t.co/fcMze8sKiX
3 days ago
How should we treat low-gradient severe #aorticstenosis? Low baseline gradient & reduced SVi predict higher #TAVR mortality. Low-gradient normal LVEF outcomes similar to high gradient: https://t.co/JB8anrFsmv. #JACCIMG #cardiotwitter #cvVHD https://t.co/Wal63fVoMy
How should we treat low-gradient severe #aorticstenosis? Low baseline gradient & reduced SVi predict higher #TAVR mortality. Low-gradient normal LVEF outcomes similar to high gradient: https://t.co/JB8anrFsmv. #JACCIMG #cardiotwitter #cvVHD https://t.co/Wal63fVoMy
4 days ago
A case report of an unusual cause of mitral stenosis in a young woman https://t.co/6ABoSJ0gug
@escardio @johncamm #EHJCaseReports #ESCCoT #ESCardioEd #CardioTwitter #openaccess https://t.co/tqcnqS6At1
A case report of an unusual cause of mitral stenosis in a young woman https://t.co/6ABoSJ0gug
@escardio @johncamm #EHJCaseReports #ESCCoT #ESCardioEd #CardioTwitter #openaccess https://t.co/tqcnqS6At1
6 days ago
Wow. Amazing day at the @BJCAstarter conference. Well done to all involved. The future of #cardiology is in great hands! #CardioEd https://t.co/9hxWVucGAt
Wow. Amazing day at the @BJCAstarter conference. Well done to all involved. The future of #cardiology is in great hands! #CardioEd https://t.co/9hxWVucGAt
2 weeks ago
521 pts TMVR registry w/ failed MVR [ViV], rings [ViR], MAC [ViMAC]. 2nd valve, >mild MR, PVL closure more in ViR vs ViMAC&ViV. Risk mortality w/ ViR vs.ViV, [HR 1.99,95% CI 1.27–3.12; P=0.003];ViMAC vs.ViV, HR 5.29, 95% CI 3.29–8.51; P<0.001]. https://t.co/fnqQdtj6kP #EchoFirst https://t.co/nkejW2KaCo
521 pts TMVR registry w/ failed MVR [ViV], rings [ViR], MAC [ViMAC]. 2nd valve, >mild MR, PVL closure more in ViR vs ViMAC&ViV. Risk mortality w/ ViR vs.ViV, [HR 1.99,95% CI 1.27–3.12; P=0.003];ViMAC vs.ViV, HR 5.29, 95% CI 3.29–8.51; P<0.001]. https://t.co/fnqQdtj6kP #EchoFirst https://t.co/nkejW2KaCo
3 weeks ago
What is this patient’s heart rhythm? @MasriAhmadMD @malamo512 @msenussiMD @AnumSaeedMD @BPierce_MD @PittCardiology #cardioed #EchoFirst https://t.co/80J7nnT9S0
What is this patient’s heart rhythm? @MasriAhmadMD @malamo512 @msenussiMD @AnumSaeedMD @BPierce_MD @PittCardiology #cardioed #EchoFirst https://t.co/80J7nnT9S0
